(Press-News.org) Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease that predominantly affects the axial skeleton.1 axSpA is an umbrella term that comprises the whole spectrum of patients with and without radiographic sacroiliitis, and joint ASAS/EULAR recommendations were published in 2022.2 Radiographic sacroiliitis classifies patients as radiographic axSpA (r-axSpA) and those patients are at risk of spinal ankyloses. High disease activity has previously been linked to accelerated radiographic spinal progression in patients with early axSpA,3 but more information is needed.
Work presented at the 2025 annual EULAR congress in Barcelona describes a potential set of predictors for spinal progression, based on data collected over 13 years in 176 patients with r-axSpA. Patients fulfilling the modified New York criteria for r-axSpA (previously termed ankylosing spondylitis) were included in this longitudinal study, and everyone was examined at baseline, and then again at 5 and 13 years. Spinal radiographs were graded according to the modified Stoke AS Spinal Score (mSASSS), and predictors for continuous change were assessed over various time periods.
Of the 176 patients included at baseline, 166 and 136 were assessed at the 5- and 13-year follow-up respectively, and 126 participated on all three occasions. Over time, there was a significant increase in spinal ankylosis (mSASSS), with a mean increase of 1.6 points from baseline to 5 years, and 2.7 from 5- to 13-year follow-up – reflecting a yearly average increase in mSASSS of 0.29 and 0.34, respectively. Sex-stratified analyses showed significant increases in both males and females.
Several factors were flagged as being significant associations when the researchers looked for predictors of progression. For example, higher C-reactive protein and being overweight or obese predicted progression in both sexes. Higher mSASSS at the start of follow-up and exposure to tumour necrosis factor inhibitors (TNFi) or bisphosphonates were associated with progression in females, whereas smoking and carrying the HLA-B27 gene were significant predictors in males.
Anna Deminger, lead author for the study, said “On a group level, the progression in spinal pathological new bone formation was slow but continued over 13 years in patients with long-standing r-axSpA.”
This study highlights the importance of inflammation as a negative prognostic marker for spinal radiographic progression. Other modifiable adverse prognostic markers were smoking and having a body mass index over 25. Of note, the higher risk of spinal radiographic progression in women exposed to TNFi or bisphosphonates needs to be further investigated.
Source
Deminger A, et al. Predictors of spinal radiographic progression over up to 13 years in patients with radiographic axial spondyloarthritis. Presented at EULAR 2025; OP0314. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B2838.
References
1. Navarro-Compán V, et al. Axial spondyloarthritis. Ann Rheum Dis 2021;80:1511–21. DOI: 10.1136/annrheumdis-2021-221035.
2. Ramiro S, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82:19–34. DOI: 10.1136/ard-2022-223296.
3. Poddubnyy D, et al. High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Ann Rheum Dis 2016;75:2114–8. DOI: 10.1136/annrheumdis-2016-209209.
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
Contact
EULAR Communications, communications@eular.org
Notes to Editors
EULAR Recommendations
EULAR School of Rheumatology
EULAR Press Releases
END
Risk factors for progression in spondyloarthritis
2025-06-13
ELSE PRESS RELEASES FROM THIS DATE:
Patient experiences In JIA
2025-06-13
A systematic review aimed to assess the specific needs for adolescents and young adults with juvenile idiopathic arthritis (JIA). Data from 1,913 patients aged range 11–30 years found that the three most common general needs were around daily activities and involvement in treatment decisions – each cited by 66% - and social life, including family and sexual considerations, which affected 55%. Other key needs in increasing order of importance were mobility, future, education, disease management, and treatment. Of the studies that focused on mental health, the need for independence, emotional ...
Patient organizations: The partner by your side
2025-06-13
At the 2025 congress of EULAR – The European Alliance of Associations for Rheumatology – two abstracts were presented that showcase how patient organisations can help to support with education for people with an RMD.
The first looked at the idea of ‘introduction maps’. To do this, patient experts and healthcare professionals working with ReumaNet in Belgium researched the information needs of new RMD patients. The results suggested a need for high-quality information with one distribution ...
Nurses: A critical role for people with RMD
2025-06-13
New studies shared at the 2025 annual EULAR congress in Barcelona reinforce that position, highlighting the benefits that nurse-led care can bring for both patients and healthcare systems.
Nurse-led care and self-monitoring can both support treat-to-target (T2T) approaches.2,3 Combining self-monitoring with nurse support during the initiation of urate-lowering therapy in people with gout could help reduce physician visits and costs while maintaining or improving quality of care. Work shared by Jeffrey van der Ven looked at estimating the cost-effectiveness ...
Online information for patients needs guidance
2025-06-13
Recommendations stress that communication impacts treatment outcomes and shared decision-making between patients and physicians. Health literacy is an important aspect in this regard, and a person’s understanding of their condition can impact how they are able to use health information.2 There is growing evidence to suggest that internet-based information is an important tool for improving communication with healthcare professionals – and for many patients it plays a central role in their experience.3
New work presented at the 2025 annual EULAR ...
The many ways that AI enters rheumatology
2025-06-13
High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in systemic sclerosis (SSc). But AI-assisted interpretation has the potential to improve the quantification and characterisation of SSc-ILD, making it a powerful tool for monitoring. Francesca Motta offered new data from an observational study pitting AI-assisted analysis against two radiologists with expertise in thoracic imaging. Results showed that the AI outperformed visual scoring in assessing the progression of fibrosis in patients with SSc-ILD, and showed more significant correlation with values from pulmonary ...
Pregnancy outcomes in autoinflammatory disease
2025-06-13
To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual congress of EULAR – showcased findings from 97 women with an autoinflammatory disease. The most common diagnoses were FMF (81%), followed by undifferentiated systemic autoinflammatory diseases (USAID), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndromes (CAPS), Still's disease, recurrent pericarditis, mevalonate kinase deficiency, A20 haploinsufficiency, and other ...
The value of physical activity for people with RMD
2025-06-13
Several sessions at the 2025 annual congress of EULAR, which took place in Barcelona, focused on the value of physical activity for people with a variety of RMD – as well as the potential barriers to implementing these programs in the real world.
Previous trials have demonstrated that long-standing, personalised supervised exercise therapy is more effective than usual care after 1 year in people with severe functional limitations due to rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA).3,4 David Ueckert and colleagues set out to evaluate ...
First data from the EULAR RheumaFacts project
2025-06-13
New work presented at the 2025 congress of EULAR – The European Alliance of Associations for Rheumatology – in Barcelona described RMD health-related indicators from all EULAR member countries, collected as part of the RheumaFacts project – a study identifying potential inequities between countries.
Data were collected on a diverse range of topics, including access to reimbursed physiotherapy and psychological care, the possibility for patients to self-refer to rheumatologists in the public sector, the number of rheumatology departments and rheumatologists, and treatment availability. So far, 31 countries have submitted data.
The ...
Research spotlight: Preventing stalling to improve CAR-T cells’ efficacy against tumors
2025-06-13
Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program and the Paula J. O'Keeffe Endowed Chair of the Mass General Cancer Center, is senior author and Stefanie Bailey, PhD, Hana Takei, and Giulia Escobar, PhD of the Krantz Family Center for Cancer Research at Massachusetts General Hospital are co-lead authors of a paper published in Science Translational Medicine, “IFN-g-resistant CD28 CAR-T cells demonstrate increased survival, efficacy, and durability in multiple murine ...
c-Fos expression differentially acts in the healthy brain compared with Alzheimer’s disease
2025-06-13
Immediate-early genes (IEGs), including c-Fos, are integral to the brain's response to stimuli. Initially identified as a proto-oncogene, c-Fos is essential for neural activity, synaptic plasticity, and stress responses. While its transient expression supports memory formation in healthy brains, chronic overexpression in AD exacerbates neurotoxicity and cognitive decline. This review synthesizes findings from postmortem studies, animal models, and cell cultures to elucidate the dual roles of c-Fos and its mechanisms in AD pathogenesis.
Expression of c-Fos in Brain Regions and Cell Types
c-Fos is expressed in specific brain regions such as the hippocampus, amygdala, and cortex, ...